|
[1]
|
Rees, F., Doherty, M., Grainge, M.J., et al. (2017) The Worldwide Incidence and Prevalence of Systemic Lupus Erythe-matosus: A Systematic Review of Epidemiological Studies. Rheumatology, 56, 1945-1961. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Liu, Z. and Davidson, A. (2012) Taming Lupus—A New Un-derstanding of Pathogenesis Is Leading to Clinical Advances. Nature Medicine, 18, 871-882. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Gottschalk, T.A., Tsantikos, E. and Hibbs, M. (2015) Pathogenic Inflamma-tion and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Frontiers in Immunology, 6, Article 550. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
McGeachy, M.J., Cua, D.J. and Gaffen, S.L. (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity, 50, 892-906. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Burkett, P.R., Meyer Zu Horste, G. and Kuchroo, V. (2015) Pouring Fuel on the Fire: Th17 Cells, the Environment, and Autoimmunity. Journal of Clinical Investigation, 125, 2211-2219. [Google Scholar] [CrossRef]
|
|
[6]
|
Ruiz De Morales, J.M.G., Daudén, E., et al. (2019) Critical Role of Interleukin (IL)-17 in Inflammatory and Immune Disorders: An Updated Review of the Evidence Focusing in Controversies. Autoimmunity Reviews, 19, Article 102429. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Cao, H, Su, S, Yang, Q, et al. (2021) Metabolic Profiling Re-veals Interleukin-17A Monoclonal Antibody Treatment Ameliorate Lipids Metabolism with the Potentiality to Reduce Cardiovascular Risk in Psoriasis Patients. Lipids in Health and Disease, 20, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Kim, H.J., Seo, S.J., Kim J.Y., et al. (2020) IL-17 Promotes Os-teoblast Differentiation, Bone Regeneration, and Remodeling in Mice. Biochemical and Biophysical Research Communi-cations, 524, 1044-1050. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Tu, Z, Xiong, J, Xiao, R, et al. (2019) Loss of miR-146b-5p Pro-motes T Cell Acute Lymphoblastic Leukemia Migration and Invasion via the IL-17A Pathway. Journal of Cellular Bio-chemistry, 120, 5936-5948. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Vincent, F.B., Northcott, M., et al. (2013) Clinical Associations of Serum Interleukin-17 in Systemic Lupus Erythematosus. Arthritis Research & Therapy, 15, Article No. R97. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Mok, M.Y., Wu, H.J., Lo, Y. and Lau, C.S. (2010) The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus. The Journal of Rheumatology, 37, 2046-2052. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Ebrahimi Chaharom, F., Asghar Ebrahimi, A., et al. (2023) Associa-tion of IL-17 Serum Levels with Clinical Findings and Systemic Lupus Erythematosus Disease Activity Index. Immuno-logical Medicine, 46, 175-181. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kwan, B.C., Tam, L.-S., et al. (2009) The Gene Expression of Type 17 T-Helper Cell-Related Cytokines in the Urinary Sediment of Patients with Systemic Lupus Erythematosus. Rheumatology, 48, 1491-1497. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Sippl, N., Faustini, F., et al. (2021) Arthritis in Systemic Lupus Erythematosus is Characterized by Local IL-17A and IL-6 Expression in Synovial Fluid. Clinical and Experimental Im-munology, 205, 44-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lubberts, E. (2015) The IL-23-IL-17 Axis in Inflammatory Arthritis. Nature Reviews Rheumatology, 11, 415-429. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Chen, X., Jiang, X., Doddareddy, R., et al. (2018) Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice. Journal of Pharmacology and Experimental Therapeutics, 365, 140-155. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Bridgewood, C., Newton, D., Bragazzi, N., et al. (2021) Unexpected Connections of the IL-23/IL-17 and IL-4/IL-13 Cytokine Axes in Inflammatory Arthritis and Enthesitis. Seminars in Immunology, 58, Article 101520. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kyttaris, V.C., Kampagianni, O. and Tsokos, G.C. (2013) Treat-ment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice. BioMed Research International, 2013, Article ID: 861028. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Griffiths, C.E., Reich, K., et al. (2015) Comparison of Ixekizumab with Etanercept or Placebo in Moderate-to-Severe Psoriasis (UNCOVER-2 and UNCOVER-3): Results from Two Phase 3 Randomised Trials. The Lancet, 386, 541-551. [Google Scholar] [CrossRef]
|
|
[20]
|
McInnes, I.B., Mease, P.J., et al. (2015) Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, in Patients with Psoriatic Arthritis (FUTURE 2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 386, 1137-1146. [Google Scholar] [CrossRef]
|
|
[21]
|
Pavelka, K., Kivitz, A., et al. (2017) Efficacy, Safety, and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: A Randomized, Double-Blind Phase 3 Study, MEASURE 3. Arthritis Research & Therapy, 19, Article No. 285. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Satoh, Y., Nakano, K., Yoshinari, H., et al. (2018) A Case of Re-fractory Lupus Nephritis Complicated by Psoriasis Vulgaris That Was Controlled with Secukinumab. Lupus, 27, 1202-1206. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
De Souza, A., Ali-Shaw, T., Strober, B.E., Franks, A.G. et al. (2011) Successful Treatment of Subacute Lupus Erythematosus with Ustekinumab. Archives of Dermatology, 147, 896-898. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Leonardi, C.L., Kimball, A.B., et al. (2008) Ef-ficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1). The Lancet, 371, 1665-1674. [Google Scholar] [CrossRef]
|
|
[25]
|
McInnes, I.B., Kavanaugh, A., et al. (2013) Ef-ficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial. The Lancet, 382, 780-789. [Google Scholar] [CrossRef]
|
|
[26]
|
Van Vollenhoven, R.F., Hahn, B.H., et al. (2018) Efficacy and Safety of Ustekinumab, an IL-12 and IL-23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Re-sults of a Multicentre, Double-Blind, Phase 2, Randomised, Controlled Study. The Lancet, 392, 1330-1339. [Google Scholar] [CrossRef]
|